Core Viewpoint - The company has announced adjustments to the implementation location and timeline of its convertible bond fundraising project, specifically the CDMO project, extending the expected completion date to June 2029 [2][4][9]. Fundraising Overview - The company plans to issue convertible bonds totaling 822.35 million yuan, with a net amount of approximately 811.74 million yuan after deducting issuance costs [2][3]. - The funds will be allocated to the high-end pharmaceutical intermediates and active pharmaceutical ingredients CDMO industrialization project, with a total investment of 863.51 million yuan, of which 811.74 million yuan is expected to be funded from the raised capital [3][4]. Project Adjustment Details - The implementation location for certain workshops and auxiliary facilities of the CDMO project will be adjusted within the original factory area, and the project timeline has been extended to June 2029 [2][4][6]. - The adjustments are made to optimize space utilization and reduce construction and operational costs while complying with government requirements [6][9]. Reasons for Delay - The project was initially scheduled for completion between June 2024 and June 2026, but delays occurred due to funding constraints and the need for additional government approvals, which are expected to take 4-6 months [6][7]. - Market conditions have changed, leading to a decrease in demand for CDMO services, prompting the company to reassess the project timeline and prioritize certain facilities [7][8]. Impact of Adjustments - The adjustments will not change the total investment amount, project scale, or the use of raised funds, and are deemed necessary for the project's successful implementation [9][10]. - The company has followed the required approval processes for these adjustments, ensuring compliance with relevant regulations [9][10].

Core Viewpoint - The company, Shanghai Haoyuan Pharmaceutical Co., Ltd., is adjusting the implementation locations and delaying the timeline for its convertible bond fundraising project, specifically for the CDMO project, while ensuring that the total investment amount and production capacity remain unchanged [1][6]. Fundraising Overview - The company has received approval from the China Securities Regulatory Commission to issue convertible bonds totaling RMB 822.35 million, with a maturity of 6 years and a face value of RMB 100 per bond [1][2]. - The funds will be stored in a dedicated account, and the company has signed a tripartite/four-party supervision agreement with the sponsor and the bank [1]. Investment Project Details - The total investment for the high-end pharmaceutical intermediates and raw materials CDMO industrialization project (Phase I) is RMB 863.51 million, with RMB 811.74 million planned to be funded from the raised capital [2][3]. Adjustments and Delays - The project site is located in the chemical park in Chengwu County, Heze City, Shandong Province, covering approximately 158 acres [3][4]. - Adjustments include relocating certain workshops and auxiliary facilities to optimize space and reduce costs, without affecting the total investment or production capacity [4][6]. - The project timeline has been extended to June 2029 due to delays in funding and the need for additional government approvals [5][6]. Impact of Adjustments - The adjustments are based on practical project implementation conditions and do not alter the investment content or total amount, ensuring no significant adverse effects on the company's operations [6][7]. - The company has followed necessary approval procedures for these adjustments, complying with relevant regulations [6][7].